{"id":"W4412940313","doi":"10.1136/jitc-2024-010777","title":"Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"American Society of Clinical Oncology","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Melanoma; Pharmacodynamics; Internal medicine; Pharmacokinetics; Clinical endpoint; Oncology; Adverse effect; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Cancer; Clinical trial; Gastroenterology; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00276166,0.0007436578,0.001324354,0.0002436472,0.0002561751,0.0009185384,0.0006735082,0.0008018757,0.001793106],"category_scores_gemma":[0.001339969,0.0002945519,0.001463171,0.000323774,0.0006033038,0.0006759202,0.0004164725,0.001607223,0.0003287995],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006152097,"about_ca_system_score_gemma":0.0009574923,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005482166,"about_ca_topic_score_gemma":0.001754269,"domain_scores_codex":[0.9992558,0.0004333234,0.00005214733,0.0001212435,0.00006893584,0.00006849143],"domain_scores_gemma":[0.9990402,0.0002129371,0.000276925,0.00008334708,0.00005851964,0.000328151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8736692,0.0118811,0.02364336,0.001693813,0.004044733,0.0001942698,0.0001430585,0.001629062,0.01453783,0.0002396726,0.003776007,0.06454796],"study_design_scores_gemma":[0.7548849,0.1842727,0.05040904,0.0001449198,0.002207763,0.0004064505,0.0001086796,0.001128913,0.002060983,0.0003193143,0.004011488,0.00004483502],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828488,0.01224116,0.0001961954,0.0005417938,0.0001309437,0.0008427878,0.001235598,0.00003338525,0.001929284],"genre_scores_gemma":[0.9906762,0.003431209,0.0006593751,0.0008428836,0.0002330838,0.0006235921,0.002429087,0.00001041635,0.001094012],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00276166,"threshold_uncertainty_score":0.01460522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00830114669991602,"score_gpt":0.2984537980471647,"score_spread":0.2901526513472487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}